Stock analysts at Zacks Research increased their Q1 2025 earnings per share estimates for BioMarin Pharmaceutical in a ...

BioMarin said it expects to have pre-tax charges of around $30 million as a result of the latest round of job cuts, adding that all the affected employees were notified by 28th August and the ...

While the job market is tough for life sciences professionals right now, it won’t always be. Employers must continue striving ...

Net income was up a robust 525% year over year, rising to $125 million. BioMarin Pharmaceutical exceeded earnings and revenue expectations in its Q4 2024 financial results. BioMarin Pharmaceutical ...

A slimmed-down BioMarin started the new year with a bang, hitting the annual J.P. Morgan Healthcare Conference with the goal of tapping its skillset to strike deals that bolster its pipeline of ...

On the call from BioMarin management today are Alexander ... allowing us to make an even greater impact for our patients, our employees and our shareholders. Looking ahead in 2025, we expect ...

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development ...

Alexander Hardy; President, Chief Executive Officer, Director; Biomarin Pharmaceutical Inc Brian Mueller; Chief Financial Officer, Executive Vice President; Biomarin Pharmaceutical Inc Cristin ...